Holen Sie sich die Stockscreener-App
0.0942
3.88%
-0.0038
Handel nachbörslich:
.09
-0.0042
-4.46%
Profusa Inc Aktie (PFSA) Neueste Nachrichten
Renowned Greek surgeon adopts new tech to track tissue oxygen at home - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Profusa (NASDAQ: PFSA) outlines reverse split plan to address Nasdaq listing rules - Stock Titan
Profusa, Inc.Common Stock (NQ: PFSA - FinancialContent
Profusa restructures senior secured convertible notes - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Profusa expands European footprint with French distributor partnership By Investing.com - Investing.com Nigeria
Profusa expands European footprint with French distributor partnership - Investing.com India
Profusa Bolsters European Commercial Network with New French Distributor, MedSell - The Manila Times
Profusa Bolsters European Commercial Network With New French Distributor, MedSell - 富途牛牛
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Profusa stock whipsaws: PFSA dips premarket after 78% surge on debt restructuring - ts2.tech
Manufacturing Stocks To Add to Your Watchlist – December 30th - Defense World
Nio, Profusa, Nike, FTAI Aviation And Under Armour: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Profusa (PFSA) Stock Analysis Report | Financials & Insights - Benzinga
Profusa Stock Soars—To 12 Cents—On Debt Restructuring - Sahm
Profusa (PFSA) Stock: Announces Key Changes to Senior Secured Convertible Notes for Stronger Financial Health - parameter.io
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Nasdaq Trading Activity: Profusa Leads High-Volume Movers on December 30, 2025News and Statistics - IndexBox
Profusa amends securities purchase agreement to allow for $5 million note sale - Investing.com Nigeria
Here’s Why Profusa Stock (PFSA) Rocketed Today - TipRanks
US Stocks Lower; Home Price Growth Eases in October - Sahm
Profusa Restructures Senior Secured Convertible Notes; Shares Jump Pre-Bell - MarketScreener
Profusa restructures convertible note to reduce dilution, increase flexibility - Investing.com
Profusa amends securities purchase agreement to allow for $5 million note sale By Investing.com - Investing.com South Africa
Profusa restructures convertible note to reduce dilution, increase flexibility By Investing.com - Investing.com South Africa
Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35 - The Manila Times
Profusa Signs Amendment No. 3 to Securities Purchase Agreement With Ascent Partners Fund - TradingView — Track All Markets
[8-K] Profusa, Inc. Reports Material Event | PFSA SEC FilingForm 8-K - Stock Titan
Digital health firm revamps debt terms to reduce share dilution - Stock Titan
PFSA SEC FilingsProfusa Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Profusa amends equity deal and convertible note terms - MSN
[424B3] Profusa, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Profusa amends securities agreements with Ascent Partners Fund - Investing.com India
Profusa Amends Equity Deal and Convertible Note Terms - TipRanks
Profusa amends securities agreements with Ascent Partners Fund By Investing.com - Investing.com UK
Profusa Updates Multiple Financing Agreements With Ascent Partners Fund - TradingView — Track All Markets
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Profusa (NASDAQ:PFSA) versus ReShape Lifesciences (OTCMKTS:RSLSD) Financial Contrast - Defense World
Profusa’s Lumee oxygen monitoring meets key endpoints in PAD study By Investing.com - Investing.com Nigeria
Profusa’s Lumee oxygen monitoring meets key endpoints in PAD study - Investing.com
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - The Manila Times
Profusa U.S. study met primary end points as presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - marketscreener.com
Profusa U.S. Study Met Primary End Points As Presented At Late Breaking Clinical Trials At Paris Vascular Insights 2025 - TradingView — Track All Markets
Profusa (Nasdaq: PFSA) U.S. Lumee PAD study hits endpoints, backs potential FDA filing - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - The Manila Times
Profusa (Nasdaq: PFSA) to share US pilot PAD Lumee data at LINC 2026 in Leipzig - Stock Titan
The growth track for Profusa Inc (PFSA) has changed recently - setenews.com
Profusa, Inc. Common Stock (PFSA) -5.4% in Intraday Trading: Decline Despite Positive Clinical Update - Stocks Telegraph
1.31%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):